Abstract: Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.

Abstract: Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.

Abstract: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2.

Abstract: Monoclonal antibodies, including chimeric and humanized antibodies, that bind both acylated and unacylated human ghrelin are disclosed. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Such antibodies and antigen-binding portions thereof are useful for neutralizing ghrelin activity in, for example, a human subject suffering from a disorder in which ghrelin activity is detrimental.

Abstract: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope fall within the scope of the invention and may be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammals.

Abstract: Monoclonal antibodies, including humanized and chimeric antibodies, that bind acylated and unacylated human ghrelin are provided. Such monoclonal antibodies can be full-length, or an antigen-binding portion thereof, and are useful for neutralizing ghrelin activity, e.g., in a human subject suffering from a disorder in which ghrelin activity is detrimental.

Abstract: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-3. These antibodies are useful as diagnostic and therapeutic reagents.

Abstract: Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such ICE LAP-6 for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.

Abstract: Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10?8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.